What is the recommended tapering schedule for discontinuing 40mg of prednisone (corticosteroid)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 12, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Tapering 40mg Prednisone: Recommended Schedule

For most conditions requiring 40mg prednisone, reduce the dose to 10mg daily within 4-8 weeks, then taper by 1mg every 4 weeks until discontinuation. 1, 2

Initial Rapid Taper Phase (Weeks 1-8)

Reduce from 40mg to 10mg over 4-8 weeks using the following approach: 3, 1, 2

  • Decrease by 5mg every 1-2 weeks until reaching 10mg daily 2
  • Administer as a single morning dose before 9am to minimize adrenal suppression 4
  • Monitor for disease flare and adverse effects every 4-8 weeks during this phase 3, 1

This initial rapid taper is supported by the European League Against Rheumatism guidelines for multiple rheumatic conditions and represents the standard approach across disease states. 3, 1

Maintenance Taper Phase (After Week 8)

Once at 10mg daily, slow the taper to 1mg decrements every 4 weeks until complete discontinuation: 3, 1, 2

  • This slower taper minimizes risk of adrenal insufficiency and disease relapse 2
  • Continue single morning dosing 4
  • Follow-up every 8-12 weeks during this phase 3, 1

The European League Against Rheumatism emphasizes this slower taper at lower doses is critical, as the adrenal axis becomes increasingly vulnerable below 10mg daily. 3, 2

Special Considerations for Doses Below 5mg

If night pain or breakthrough symptoms occur below 5mg daily, consider split dosing (e.g., morning and evening doses): 3, 1

  • However, persistent symptoms should prompt reconsideration of the diagnosis 3
  • Split dosing increases adrenal suppression risk but may be necessary for symptom control 3, 1

Managing Relapse During Taper

If disease flares during tapering, increase back to the pre-relapse dose, then: 3, 1

  • Gradually decrease within 4-8 weeks to the dose where relapse occurred 3, 1
  • Hold at that dose longer before attempting further reduction 3
  • Consider adding steroid-sparing agents (e.g., methotrexate 7.5-10mg weekly) if multiple relapses occur 3, 1

Duration of Therapy

Total treatment duration typically ranges 4-12 months depending on the underlying condition: 3, 2

  • Polymyalgia rheumatica often requires 12+ months 3
  • Bullous pemphigoid typically needs 4-12 months 3, 2
  • Acute conditions may require shorter courses 2

Short-Course Exception (≤2 Weeks)

For acute conditions treated with 40mg for only 1-2 weeks, tapering may not be necessary: 5, 6, 7

  • Research shows no difference in relapse rates between tapered and non-tapered short courses 5, 6
  • No adrenal suppression was demonstrated after 8-day courses 5
  • However, the FDA label recommends gradual withdrawal after long-term therapy 4

Critical Pitfalls to Avoid

Never taper faster than 1mg every 4 weeks below 10mg daily - this dramatically increases adrenal crisis risk and disease relapse: 1, 2

  • Tapering too quickly at low doses is the most common error 2
  • Failing to monitor for relapse during tapering leads to delayed recognition of flares 1, 2
  • Abrupt discontinuation after prolonged therapy can precipitate adrenal crisis 4

Do not use divided doses unless specifically indicated (e.g., breakthrough symptoms <5mg), as this increases HPA axis suppression: 4, 7

Monitoring Requirements

Assess clinical response and inflammatory markers at regular intervals: 3, 1

  • Every 4-8 weeks during first year 3, 1
  • Every 8-12 weeks during second year 3, 1
  • More frequently if symptoms suggest relapse 3, 1

Initiate osteoporosis prophylaxis if treatment expected >3 months: 3

  • Calcium 800-1000mg daily plus vitamin D 400-800 units daily 3, 8
  • Consider baseline bone density screening 3

References

Guideline

Management of High-Dose Prednisone for Rheumatic Valve Flare and Deprescribing

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Guidelines for Prednisone Tapering from 40 mg

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

Use and abuse of systemic corticosteroid therapy.

Journal of the American Academy of Dermatology, 1979

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.